Consider a Genomic Cancer Test to Find the Potential Driver of Your CRC

Genomic cancer testing helps detect changes in a tumor’s DNA, called genomic alterations, that can determine how your cancer behaves and why it grows or spreads. The results of the test can help you and your healthcare provider (HCP) create a personalized plan that is tailored to your diagnosis.

Genomic cancer tests can find and identify a range of alterations. One example is called an NTRK gene fusion.

Cancers that Test Positive for NTRK Gene Fusions can be Present in Many Parts of the Body, Including the Colon

When an NTRK gene joins together, or fuses, with a different, unrelated gene, it creates certain proteins (TRK fusion proteins) that can cause cancer cells to multiply and form a tumor.

Studies suggest NTRK gene fusions are found in a range of 0.2% to 2.7% of all colorectal cancer cases and in more than 3% of MSI-H CRC cases.

Bayer is Sponsoring the Test4TRK Program to Provide Genomic Cancer Testing for Eligible CRC Patients at NO COST

Bayer launched the Test4TRK program to sponsor genomic cancer testing for NTRK gene fusions for eligible metastatic colorectal cancer (mCRC) patients with confirmed MSI-H status.

As part of this program, Bayer will cover the cost of the test regardless of the results, treatment decision and insurance coverage.

Enrolling in the Test4TRK Program is Easy - Take 3 Steps!

1. Download the Test Requisition Form from www.Test4TRK.com
2. Speak to your HCP about getting tested and if you are eligible
3. Based on the results, discuss appropriate treatment options with your HCP

ASK YOUR HEALTHCARE PROVIDER FOR NTRK GENE FUSION TESTING TO IDENTIFY ACTIONABLE DRIVERS AND POTENTIAL TREATMENT OPTIONS
Why should I care about NTRK gene fusions?
NTRK gene fusions can drive tumor growth, which means a fusion could be causing cancer cells to multiply and form a tumor. Studies suggest NTRK gene fusions occur in more than 3% of MSI-H CRC cases.

How do I know if I have MSI-H mCRC?
If you have been diagnosed with metastatic colorectal cancer (mCRC), talk to your HCP to find out if you have High MicroSatellite Instability (MSI-H).

Why should I consider a genomic cancer test?
Genomic cancer testing is the best method to uncover actionable alterations, which means that they could be matched to either an approved therapy or a drug in a clinical trial.

What is the difference between genetic testing and genomic cancer testing?
Genomic cancer testing helps identify what may be causing your tumor to grow and spread by looking at your entire genome, whereas genetic testing looks at inherited traits or disease risks that may be passed down from generation to generation based on a specific set of genes.

Am I eligible for testing through the Test4TRK program?
Any mCRC patient with MSI-H status and a previously biopsied tumor is eligible to enroll in the Test4TRK program. Patients who have not previously undergone a biopsy may still enroll in the program, but should work with their HCP to collect the tumor sample and cover any associated expenses.

Is this relevant for me if I am already receiving treatment?
Yes, genomic cancer testing and the Test4TRK Program are still relevant because understanding your tumor's genomic profile may inform alternate or future treatment options. You should discuss next steps with your HCP.

Who should I contact to enroll in Test4TRK?
Please consult your HCP to learn more about the Bayer-sponsored Test4TRK program and to confirm if you are eligible to receive a genomic cancer test at no cost.

What if I don’t have health insurance? Will I have any financial responsibility?
Any mCRC patient with MSI-H status is eligible for Test4TRK regardless of insurance coverage.

How do I get my results and how long will it take? What should my next steps be?
Once your HCP submits your tumor sample and registration form, you should expect test results within 14 calendar days. Discuss the results with your HCP as well as potential treatment options.

We submitted the test and received the results, now what?
Following a report on the test results, talk to your HCP about a potential treatment plan based on the NTRK gene fusion status identified.